Cytokinetics CYTK announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.
Earnings and Revenue
Sell-side analysts are expecting Cytokinetics's loss per share to be near 70 cents on sales of $6.32 million.
In the same quarter last year, Cytokinetics reported earnings per share of 16 cents per share on revenue of $33.1 million. If the company were to match the consensus estimate when it reports Thursday, EPS would have fallen 537.5 percent. Sales would be down 80.93 percent on a year-over-year basis.
Here's how the Cytokinetics's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
EPS Estimate | -0.61 | -0.59 | -0.27 | -0.4 |
EPS Actual | -0.6 | -0.6 | -0.62 | 0.16 |
Stock Performance
Over the last 52-week period, shares are down 23.13 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.
Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The popular rating by analysts on Cytokinetics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
Cytokinetics' Q4 conference call is scheduled to begin at 4:00 p.m. ET and can be accessed here: https://cytokinetics.com/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.